Wall Street is positive on PhaseBio Pharmaceuticals Inc (PHAS). On average, analysts give PhaseBio Pharmaceuticals Inc a Hold rating. The average price target is $4.5, which means analysts expect the stock to increase by 3650.00% over the next twelve months. That average ranking earns PhaseBio Pharmaceuticals Inc an Analyst Rating of 5, which is better than 5% of stocks based on data compiled by InvestorsObserver.
Wall Street analysts are rating PHAS a Hold today. Find out what this means to you and get the rest of the rankings on PHAS!